Studying lung immunity and microbes after tuberculosis exposure in adults
Looks at lung immune response and airway microbes in adults recently exposed to tuberculosis.
Plain-language title generated from the registry record
Registry title: Lung Innate Immunity and Microbiome After Tuberculosis Exposure
Key facts
- Where
- London and Oxford, United KingdomSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06526689, who can take part
Where in United Kingdom
- Grove Building, Royal Free NHS Foundation TrustLondon, United KingdomTaking people
- Centre for Clinical Vaccinology and Tropical MedicineOxford, United KingdomTaking people
- Churchill HospitalOxford, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Oxford
- Trial code
- NCT06526689
- Record updated
- 22 January 2025
- Original description
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposureRead full original descriptionShow less
Investigating the Impact of the Pulmonary Innate Immune Response and Microbiome After Exposure to Mycobacterium Tuberculosis
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure
Inclusion: Adults aged 18-65 years; Resident in or near London or Oxford for the duration of the study period; Provide written informed consent; Willing to allow the investigators to review the volunteer's review NHS care record, medical history, blood results and radiographs; Able and willing (in the investigator's opinion) to comply with all study requirements; Group A and B Specific Inclusion Criteria; Have undergone screening for TB through NHS services (including IGRA testing +/- CXR where indicated); Close contact with a sputum smear positive TB case within the last 12 weeks.
Exclusion: Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment or during the trial follow up period; Previous diagnosis or treatment for TB disease or latent TB infection; Previous receipt of any investigational TB vaccines or aerosolised BCG; Concurrent use of oral, inhaled or systemic steroid medication or use for more than 14 days within the last 6 months (steroids used as a cream or ointment are permissible), or the use of other immunosuppressive agents concurrently or for more than 14 days within the last 6 months; Administration of a live vaccine within the preceding 28 days prior to enrolment; Administration of any other non-live vaccine within the preceding 14 days prior to enrolment; History of close contact with case of TB, or previous contact tracing by TB services; History of anaphylaxis or any allergy likely to be exacerbated by any essential study procedure; History of currently poorly controlled of airways disease (including asthma), current cancer (except BCC of the skin or CIS of the cervix), bleeding disorder, or drug or alcohol abuse; Any significant autoimmune conditions or immunodeficiency (including HIV); Any other significant disease, disorder, or finding, which, in the opinion of the investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data; Group C Specific Exclusion Criteria; Clinical, radiological, or laboratory evidence of current active TB disease; Clinically Significant abnormalities in spirometry; Use of antibiotics in the past 4 weeks; Administration of immunoglobulins and/or any blood products within the three months preceding the planned study; Pregnancy or intention to become pregnant during study period.